Phentermine vs Ozempic: Cost, Efficacy, and Which Is Right for You

Phentermine vs Ozempic: Cost, Efficacy, and Which Is Right for You

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Phentermine and Ozempic treat obesity through different mechanisms, at different price points, with different outcomes. This comparison covers what the clinical data shows, who each medication is appropriate for, and how the cost math works out.

How do they compare at a glance?

Phentermine costs $15–50/month and produces 5–7% average body weight loss; semaglutide (Wegovy at 2.4mg) costs $129–1,349/month and produces approximately 14.9% average weight loss. That is a cost gap of 3–90x for roughly double the clinical efficacy.

	Phentermine	Ozempic / Semaglutide
Mechanism	Sympathomimetic amine (stimulant)	GLP-1 receptor agonist
FDA approval	Short-term weight management (1959)	T2D (Ozempic); obesity (Wegovy, 2021)
Controlled substance	Yes — Schedule IV	No
Average weight loss	5–7% body weight	14.9% (Wegovy 2.4mg, STEP 1 trial)
Monthly cost (generic/compounded)	$15–50/mo	$129–199/mo compounded; $936–1,349/mo brand
Route	Oral pill	Weekly injection (oral Wegovy also available)
Duration	Short-term (≤12 weeks per FDA label)	Long-term chronic use
CV risk	Increases heart rate and blood pressure	Reduces cardiovascular events
Best for	Budget-constrained patients; short-term appetite suppression	Patients seeking maximum efficacy; long-term management

Pricing last verified April 2026. We update pricing data monthly.

---

How does phentermine work?

Phentermine suppresses appetite by triggering norepinephrine and dopamine release in the hypothalamus — the same brain region that regulates hunger. Because of its amphetamine-like structure, it functions as a stimulant: heart rate rises, appetite falls, energy increases.

Drug class: Sympathomimetic amine Schedule: IV controlled substance (federal) Standard dose: 37.5mg once daily (generic); 8mg three times daily (Lomaira) Available as generic: Yes — widely available, including via GoodRx

Phentermine was FDA-approved in 1959, which means it has a long real-world safety record but was studied before modern cardiovascular outcome trial standards. The FDA label specifies short-term use, generally interpreted as up to 12 weeks. Many obesity medicine specialists prescribe it for longer durations off-label, but that use is not FDA-sanctioned.

---

How does Ozempic / semaglutide work?

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which signals satiety to the brain, slows gastric emptying, and improves insulin sensitivity. Unlike phentermine's stimulant effect, semaglutide's appetite suppression works through gut-brain signaling rather than norepinephrine release.

Important dosing distinction: "Ozempic" and "Wegovy" are both semaglutide, but they are different products:

• Ozempic (0.5mg, 1mg, 2mg): FDA-approved for type 2 diabetes management, not obesity
• Wegovy (up to 2.4mg): FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity

When comparing weight loss outcomes, the relevant formulation is Wegovy at 2.4mg — not the lower Ozempic doses used for diabetes. The weight loss figures cited in most news coverage and in telehealth marketing refer to Wegovy/semaglutide 2.4mg unless otherwise specified.

Compounded semaglutide — available from telehealth providers at $129–199/mo — contains the same active ingredient as brand-name semaglutide, but is manufactured by third-party 503B compounding pharmacies rather than Novo Nordisk. It is not FDA-approved or bioequivalent-rated; patients should understand this distinction when evaluating options.

---

What do the weight loss results actually show?

Semaglutide at 2.4mg (Wegovy) produces roughly twice the weight loss of phentermine in clinical trials, but the comparison is not a direct head-to-head trial.

Phentermine: Clinical trials show a mean of 5–7% body weight loss at 12 weeks compared to placebo. For a 220-pound person, that is 11–15 pounds. These trials are older and shorter than the semaglutide registration trials, limiting direct comparison.

Semaglutide (Wegovy 2.4mg): The STEP 1 trial (NEJM, 2021) showed 14.9% mean body weight loss over 68 weeks vs. 2.4% for placebo. The STEP 5 trial (Nature Medicine, 2022) showed 15.2% over 104 weeks.

Trial	Drug	Duration	Mean Weight Loss
STEP 1 (NEJM 2021)	Semaglutide 2.4mg	68 weeks	14.9%
STEP 5 (Nat Med 2022)	Semaglutide 2.4mg	104 weeks	15.2%
Phentermine (meta-analysis)	Phentermine 37.5mg	12–24 weeks	5–7%

No randomized head-to-head trial comparing phentermine directly to semaglutide exists. The efficacy gap is real, but the study populations, durations, and endpoints differ. GLP-1 trials also produced concurrent cardiovascular outcome data (the SELECT trial showed 20% reduction in major cardiovascular events); phentermine has no equivalent cardiovascular outcome trial.

---

How do the side effect profiles compare?

The two medications produce distinct, largely non-overlapping side effect profiles that reflect their different mechanisms.

Phentermine side effects:

• Elevated heart rate and blood pressure (common; mechanism-related)
• Insomnia (20–30%)
• Dry mouth (~30%)
• Anxiety or jitteriness (~10%)
• Constipation (~15%)
• Headache

Phentermine is contraindicated in patients with uncontrolled hypertension, cardiovascular disease, hyperthyroidism, history of drug abuse, or within 14 days of MAOI use. Cardiovascular risk from phentermine is built into its pharmacology, not a secondary consideration.

Semaglutide (Ozempic/Wegovy) side effects:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Constipation or diarrhea
• Pancreatitis risk (rare; monitor symptoms)
• Potential thyroid C-cell tumor risk in rodents (FDA boxed warning; clinical significance in humans is unclear)

GI side effects from semaglutide are worst during the titration phase (weeks 1–16) and typically improve at maintenance dose. Phentermine's cardiovascular side effects persist throughout treatment.

---

What does each medication actually cost?

For most patients, cost is the decision-determining factor.

Phentermine:

• Generic 37.5mg: $15–50/month via GoodRx or local pharmacy
• Brand Adipex-P: $100–150/month (no meaningful efficacy advantage over generic)
• No insurance necessary for most patients — the generic price is low enough that GoodRx often beats insurance copays

Semaglutide:

• Brand Wegovy (2.4mg): ~$1,349/month without insurance
• Brand Ozempic (1–2mg): ~$936–1,000/month without insurance
• Compounded semaglutide (telehealth): $129–199/month
• With commercial insurance + prior auth: copays vary widely; some plans cover $0–50/month

For patients without insurance coverage for GLP-1s, compounded semaglutide through telehealth is the practical access point — at 3–4x the cost of phentermine. See our full breakdown in How Much Does Semaglutide Cost and the Best GLP-1 Weight Loss Programs for provider-level pricing.

---

Who can prescribe each medication, and how do you access them?

Phentermine has some access friction because it is a Schedule IV controlled substance. Semaglutide has cost friction but no scheduling restrictions.

Phentermine access:

• Most primary care physicians can prescribe it
• Telehealth prescribing is available but state-specific — some states require an in-person evaluation or video consultation (audio-only is insufficient under current DEA telehealth rules for Schedule IV substances)
• Providers that prescribe phentermine via telehealth include Hims, Ro, and some broader weight management platforms — verify current availability before scheduling

Semaglutide access:

• No controlled substance restrictions
• Telehealth prescribing is broadly available in all 50 states with a video consultation
• Major platforms include Hims, Ro, Henry Meds, and others — see our provider reviews for current pricing and protocols

---

How does duration of use differ?

Phentermine's FDA approval specifies short-term use only — historically interpreted as "a few weeks" and operationally applied as up to 12 weeks per prescribing cycle. This limit reflects the era of approval (1959), not specific safety findings at longer durations. Some obesity medicine specialists prescribe phentermine in intermittent cycles or continuously beyond 12 weeks as an off-label practice.

Semaglutide is designed and approved for long-term chronic use. The STEP 5 trial ran 104 weeks; real-world use continues indefinitely for patients who tolerate it and maintain benefit. Weight regain after stopping GLP-1 therapy is well-documented. Most of the weight lost returns within a year of stopping, which is why long-term use is the standard clinical recommendation for patients who respond well.

---

Can you take phentermine and Ozempic together?

Generally, combining them is not recommended as a starting point. The combination adds cardiovascular risk: phentermine raises heart rate and blood pressure; semaglutide has a neutral-to-beneficial cardiovascular profile, but adding a stimulant to a patient with cardiovascular risk factors compounds that risk.

Some obesity medicine specialists do use combination approaches — using different mechanisms to achieve greater appetite suppression — but this is not standard practice and carries limited clinical trial data. Any combination use requires direct medical supervision and documented cardiovascular risk assessment. Do not self-combine.

---

Who cannot take phentermine?

Phentermine is contraindicated in patients with:

• History of cardiovascular disease (coronary artery disease, arrhythmia, stroke, heart failure)
• Uncontrolled or severe hypertension
• Hyperthyroidism
• Glaucoma
• History of drug or alcohol abuse
• Agitated states
• Concurrent or recent (within 14 days) use of MAOIs

Phentermine should be used with caution in patients with even mild hypertension or mild valvular heart disease. Cardiovascular risk is built into phentermine's pharmacology.

---

Which medication should you choose?

The right choice depends on four factors: your budget, your cardiovascular risk profile, how much weight you need to lose, and your preference for oral vs. injectable dosing.

Phentermine is the better fit if:

• Your budget is under $75/month
• Your BMI is in the overweight/mildly obese range (25–32) and 10–15 pounds of loss would meet your goal
• You have no cardiovascular disease or hypertension
• You want a short-course treatment to break a plateau rather than long-term management
• GLP-1 medications are inaccessible or unaffordable in your situation

Semaglutide is the better fit if:

• You have BMI ≥30 (or ≥27 with a weight-related comorbidity) and need ≥15% weight loss
• You have type 2 diabetes or cardiovascular risk factors that GLP-1s actively benefit
• You can afford $129–199/month for compounded semaglutide or have insurance coverage
• You need long-term weight management rather than a short-term intervention
• You have cardiovascular disease that contraindicates phentermine

If access to GLP-1s is the constraint rather than preference, see our guides on GLP-1 alternatives and most affordable GLP-1 options.

---

How We Evaluated

This comparison is based on FDA labeling for phentermine (original NDA, 1959; current prescribing information) and semaglutide (Wegovy NDA 215256; Ozempic NDA 209637), published registration trial data (STEP 1, STEP 5, SURMOUNT-5), and independently verified pricing from provider websites and GoodRx as of April 2026. No provider has paid for placement or review. See our editorial policy for full methodology.

---

Frequently Asked Questions

Is phentermine better than Ozempic for weight loss?

No. GLP-1 medications like Wegovy (semaglutide 2.4mg) produce approximately 14.9% average body weight loss in clinical trials. Phentermine produces 5–7%. Phentermine has a much lower cost ($15–50/month vs. $129–1,349/month), which makes it the more practical choice for patients who cannot access or afford GLP-1 therapy.

How much weight can you lose with phentermine vs Ozempic?

Phentermine clinical trials show an average of 5–7% body weight loss over 12 weeks. For a 220-pound person, that is 11–15 pounds. Wegovy trials show 14.9% over 68 weeks — approximately 33 pounds for the same patient. Individual results vary significantly in both cases.

Can you take phentermine and Ozempic at the same time?

Combining them is not standard practice and is generally not recommended without specialist oversight. Phentermine raises heart rate and blood pressure; adding a stimulant to any patient with cardiovascular risk factors is not advisable without direct medical supervision and documented risk assessment.

Is phentermine cheaper than Ozempic?

Significantly cheaper. Generic phentermine costs $15–50/month via GoodRx. Compounded semaglutide (the most affordable version of semaglutide) runs $129–199/month through telehealth providers. Brand-name Wegovy costs approximately $1,349/month without insurance.

Who should not take phentermine?

Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, a history of drug abuse, agitated states, or current or recent MAOI use (within 14 days). The stimulant mechanism makes cardiovascular contraindications non-negotiable.

Can I get phentermine online?

Some telehealth platforms — including Hims and Ro — prescribe phentermine after a video consultation. Because phentermine is a Schedule IV controlled substance, state rules apply: some states require in-person evaluation; audio-only telehealth is insufficient under current DEA rules. Verify availability in your state before booking.

Which is safer, phentermine or Ozempic?

Neither is universally "safer" — safety depends on your individual risk profile. For patients with cardiovascular disease, semaglutide is the safer option and phentermine is contraindicated. For patients with GI disorders, thyroid history, or pancreatitis risk, the risk profile shifts. Both are prescription medications that require a clinical evaluation before use.

How long can you take phentermine?

The FDA label specifies short-term use, operationally interpreted as up to 12 weeks per cycle. Some providers prescribe intermittently or for longer durations off-label. Semaglutide has no equivalent duration restriction and is designed for long-term use.